Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086605 · ClinicalTrials.gov registry record · Phase 2
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01086605 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 46 participants.
The verdict
NCT01086605, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well pixantrone dimaleate works in treating patients with HER2-negative metastatic breast cancer.
Interventions
- DRUG pixantrone dimaleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01086605
The ClinicalTrials.gov registry entry for NCT01086605 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pixantrone dimaleate is the first listed.
NCT01086605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01086605 about?
NCT01086605 is a clinical study titled "Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells. PURPOSE: This randomized phase II tr...
What is the current status of trial NCT01086605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2010-05. Estimated completion is 2014-11-15.
What interventions are being tested in trial NCT01086605?
The interventions under investigation include: pixantrone dimaleate (DRUG).
Who is sponsoring clinical trial NCT01086605?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.